CorMedix to Acquire Heron’s Drug Portfolio, Targets Up to $60 Million in Annual Savings
Key Points
- CorMedix will acquire substantially all of Heron’s assets, including four commercial medicines, for cash, shares and potential future payments.
- Upfront consideration was valued at approximately $222.6 million using CorMedix’s November 6 closing share price.
- Management expects immediate earnings and free-cash-flow benefits after closing, with $45–$60 million in annualized operating savings by year-end 2027.
- Heron will remain publicly traded and evaluate new investment opportunities.
- Closing is expected in the first quarter of 2027, subject to stockholder approval, regulatory clearance and other conditions.
CorMedix Therapeutics (Nasdaq: CRMD) has agreed to acquire Heron Therapeutics’(NASDAQ: HRTX) portfolio of hospital, surgical and oncology-supportive medicines, expanding its existing institutional-care business.
The transaction adds ZYNRELEF for postoperative pain, APONVIE for postoperative nausea and vomiting, and CINVANTI and SUSTOL for chemotherapy-induced nausea and vomiting. The acquired assets generated approximately $150 million in trailing 12-month net product revenue through September 2026.
Cash, Shares and Performance-Based Payments
CorMedix will pay $145 million in cash, subject to adjustments, and issue approximately 14.6 million shares. At the November 6 closing price, the shares were worth about $77.6 million. Their value can change because the share count is fixed.
Heron could also receive up to $55 million tied to ZYNRELEF’s 2028 sales and a 5% royalty on specified products’ combined annual sales above $25 million in each of 2027–2029.
CorMedix expects to draw $75 million from a new $150 million term-loan facility at closing. Although the loan has no equity component, the acquisition itself involves share issuance and dilution.
Heron Remains Public as CorMedix Integrates the Products
Heron will exit its current operating business but retain cash, CorMedix shares, potential earn-outs and royalties. It plans to repay its credit facility and assess new investments or acquisitions. A separate agreement will exchange its convertible debt for some of the CorMedix shares it receives.
CorMedix expects the acquired assets to generate $125–$150 million in 2027 pro forma revenue. Its projected cost savings are an annualized target by year-end 2027, not guaranteed savings realized during that year.
Investor Takeaway
For CRMD investors, the deal offers diversification and potential operating efficiencies, balanced against integration risk, debt and dilution. For HRTX investors, it represents a strategic reset whose value will depend on retained assets, future payments and capital-allocation decisions.
The transaction remains subject to closing conditions; the projected financial benefits are management estimates rather than completed results.
